(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 March 2023 (23.03.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/043999 A1

(51) International Patent Classification:
A61K 31/506 (2006.01) *A61P 7/02* (2006.01)

(21) International Application Number:
PCT/US2022/043797

(22) International Filing Date:
16 September 2022 (16.09.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/245,522 17 September 2021 (17.09.2021) US
63/278,582 12 November 2021 (12.11.2021) US

(71) Applicants: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventors: **STRONY, John**; 920 US Highway 202 S, Raritan, New Jersey 08869 (US). **PETERS, Gary**; 920 US Highway 202 S, Raritan, New Jersey 08869 (US). **CHINTALA, Madhu**; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). **NESSEL, Christopher**; 555 US Highway 22 W, Bridgewater, New Jersey 08807 (US). **PERERA, Liyanage Vidya**; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **LI, Danshi**; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **LUETTGEN, Joseph M.**; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **SEIFFERT, Dietmar Alfred**; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **JONES-BURTON, Charlotte**; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(74) Agent: **LODISE, Stephanie A.** et al.; BAKER HOSTETLER, 1735 Market Street, Suite 3300, Philadelphia, Pennsylvania 19103-7501 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MILVEXIAN FOR PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISORDERS




FIG. 1

(57) Abstract: The factor Xia inhibitor milvexian has therapeutic properties useful in the treatment and/or prevention of thrombotic and thromboembolic disorders.

[Continued on next page]

WO 2023/043999 A1

Published:
— *with international search report (Art. 21(3))*